Latest Trials Latest NewsFAQ

EMORY UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1836-12-10

Employees: 10K

Market Cap: -

Website: http://www.emory.edu

Clinical Trials

Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19

Phase 3

Active, not recruiting

Conditions: Pneumonia
Severe Acute Respiratory Syndrome
Symptomatic COVID-19 Infection Laboratory-Confirmed

Interventions: Radiation: Low Dose Radiation Therapy
Other: Best Practice

First Posted Date: 2020-06-16

Last Posted Date: 2023-08-14

Lead Sponsor: Emory University

Target Recruit Count: 14

Registration Number: NCT04433949

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

Cognitive Behavioral Therapy for Insomnia for the Dementia Caregiving Dyad

Not Applicable

Completed

Conditions: Dementia
Cognitive Impairment

Interventions: Behavioral: Cognitive Behavioral Therapy for Insomnia (CBTi) via Videoconference

First Posted Date: 2020-06-11

Last Posted Date: 2023-03-20

Lead Sponsor: Emory University

Target Recruit Count: 44

Registration Number: NCT04426838

Locations: 🇺🇸
Goizueta Alzheimer's Disease Research Center, Atlanta, Georgia, United States
🇺🇸
Emory University, Atlanta, Georgia, United States

Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer

Phase 1

Recruiting

Conditions: Metastatic Skin Squamous Cell Carcinoma
Recurrent Skin Squamous Cell Carcinoma

Interventions: Biological: Cemiplimab
Radiation: Radiation Therapy
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2020-06-11

Last Posted Date: 2024-08-06

Lead Sponsor: Emory University

Target Recruit Count: 20

Registration Number: NCT04428671

Locations: 🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States

Red Blood Cell Survival in Sickle Cell Disease

Phase 1

Recruiting

Conditions: Sickle Cell Disease

Interventions: Drug: Biotin Labeled Red Blood Cells
Device: INTERCEPT Blood System

First Posted Date: 2020-06-11

Last Posted Date: 2024-12-27

Lead Sponsor: Marianne Yee

Target Recruit Count: 40

Registration Number: NCT04426591

Locations: 🇺🇸
Hughes Spalding Children's Hospital, Atlanta, Georgia, United States
🇺🇸
Childrens Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸
Grady Health System, Atlanta, Georgia, United States

Oral Anti Diabetic Agents in the Hospital

Phase 4

Recruiting

Conditions: Diabetes Mellitus

Interventions: Drug: Oral Anti-diabetes Drugs alone
Drug: Basal bolus insulin
Drug: Supplemental insulin
Device: Continuous glucose monitoring (CGM)

First Posted Date: 2020-06-04

Last Posted Date: 2024-12-12

Lead Sponsor: Emory University

Target Recruit Count: 260

Registration Number: NCT04416269

Locations: 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸
Grady Memorial Hospital, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital, Atlanta, Georgia, United States

Distress in the Pediatric Oncology Setting: Intervention Versus Natural Adaptation

Not Applicable

Completed

Conditions: Pediatric Cancer

Interventions: Other: My Special Aflac Duck (MSAD)
Behavioral: Standard of care control

First Posted Date: 2020-06-01

Last Posted Date: 2024-02-20

Lead Sponsor: Emory University

Target Recruit Count: 160

Registration Number: NCT04409301

Locations: 🇺🇸
C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States
🇺🇸
Children's of Alabama, Birmingham, Alabama, United States
🇺🇸
Children's Hospital New Orleans, New Orleans, Louisiana, United States

and more 5 locations

Nutritional Impacts of Palynziq on Patients With Phenylketonuria (PKU)

Recruiting

Conditions: Phenylketonurias

Interventions: Drug: Palynziq

First Posted Date: 2020-05-27

Last Posted Date: 2024-11-22

Lead Sponsor: Emory University

Target Recruit Count: 45

Registration Number: NCT04404530

Locations: 🇺🇸
Emory University Hospital Georgia Clinical Research Center, Atlanta, Georgia, United States
🇺🇸
The Emory Clinic, Atlanta, Georgia, United States

Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma

Phase 2

Recruiting

Conditions: Kidney Cancer
Stage III Renal Cell Cancer AJCC v8
Stage IV Renal Cell Cancer AJCC v8

Interventions: Drug: Lenvatinib
Drug: Lenvatinib Mesylate
Biological: Pembrolizumab
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2020-05-19

Last Posted Date: 2024-08-14

Lead Sponsor: Emory University

Target Recruit Count: 22

Registration Number: NCT04393350

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

Pharmacy-based Pre-exposure Prophylaxis

Not Applicable

Completed

Conditions: Human Immunodeficiency Virus

Interventions: Behavioral: Pharmacy Delivered PrEP Intervention

First Posted Date: 2020-05-19

Last Posted Date: 2024-08-26

Lead Sponsor: Emory University

Target Recruit Count: 609

Registration Number: NCT04393935

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States

Equality in Caregiving: Facilitating Caregiver Mastery Among LGBT Caregivers of PLWD

Completed

Conditions: Caregiver Burnout
Dementia

Interventions: Behavioral: Savvy Caregiver Program via Remote Learning
Behavioral: Focus group

First Posted Date: 2020-05-19

Last Posted Date: 2023-03-10

Lead Sponsor: Emory University

Target Recruit Count: 10

Registration Number: NCT04394260

Locations: 🇺🇸
Emory Goizueta Alzheimer's Disease Research Center (ADRC), Atlanta, Georgia, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy